FDA Approves New COPD Treatment — Physician’s First Watch

Medical News |
August 1, 2014

FDA Approves New COPD Treatment

By the Editors

The FDA has approved olodaterol (Striverdi Respimat) inhalation spray as a once-daily maintenance therapy for chronic obstructive pulmonary disease.

In a trial of 3100 people with COPD, those who took the medication had improved lung function, compared with those who took placebo. Like other long-acting beta-adrenergic agonists, olodaterol will include a boxed warning highlighting the increase risk for asthma-related death.

Reader Comments (4)

Camille Kilgore Other Healthcare Professional, Other, Clinical Research

It is clear that patients must always check with physician to confirm confounding asthma and COPD worsening. The variations of bronchitis, exacerbations are delineated amongst the symptomology so common in emphysema and COPD. Excited for this medication.

Leon Green. MD. FCCP. Physician, ABC. Observatorio Hospital Mexico city

Your information is allways very usefull.

Daniel FLAMMANG, MD Physician, Cardiology, Lyon, France

interesting information

BSc, MD, Physician, Endocrinology, University Hospiytal

Reasonable summary

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.